[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,453,678
  • Shares Outstanding, K 199,782
  • Annual Sales, $ 5,141 M
  • Annual Income, $ 1,287 M
  • EBIT $ 1,611 M
  • EBITDA $ 1,704 M
  • 60-Month Beta 0.79
  • Price/Sales 3.93
  • Price/Cash Flow 16.38
  • Price/Book 3.60

Options Overview Details

View History
  • Implied Volatility 39.58% (+0.01%)
  • Historical Volatility 31.37%
  • IV Percentile 70%
  • IV Rank 36.83%
  • IV High 64.77% on 10/31/25
  • IV Low 24.90% on 08/08/25
  • Expected Move (DTE 10) 5.58 (5.50%)
  • Put/Call Vol Ratio 7.17
  • Today's Volume 564
  • Volume Avg (30-Day) 365
  • Put/Call OI Ratio 1.19
  • Today's Open Interest 16,933
  • Open Int (30-Day) 15,757
  • Expected Range 95.82 to 106.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.56
  • Number of Estimates 8
  • High Estimate $1.73
  • Low Estimate $1.25
  • Prior Year $1.31
  • Growth Rate Est. (year over year) +19.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
92.18 +9.03%
on 06/02/26
106.37 -5.52%
on 06/05/26
+1.94 (+1.97%)
since 05/08/26
3-Month
89.25 +12.61%
on 03/24/26
106.37 -5.52%
on 06/05/26
+4.56 (+4.75%)
since 03/06/26
52-Week
66.74 +50.58%
on 06/23/25
112.29 -10.50%
on 01/07/26
+31.73 (+46.14%)
since 06/06/25

Most Recent Stories

More News
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

- Proposed acquisition to add VGA039, a novel investigational monoclonal antibody that targets Protein S in Phase 3 development for von Willebrand disease (VWD) - ...

INCY : 100.01 (-2.31%)
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

- Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP)

MIRM : 93.76 (+0.30%)
INCY : 100.01 (-2.31%)
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi ® /Minjuvi ® ) and lenalidomide in addition to R-CHOP, the current standard of care, compared with...

INCY : 100.01 (-2.31%)
3 Profitable Stocks for Long-Term Investors

3 Profitable Stocks for Long-Term Investors

AZO : 3,072.46 (-1.41%)
INCY : 100.01 (-2.31%)
AMG : 340.52 (+1.10%)
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 47 th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 8:40 a.m. EDT. The...

INCY : 100.01 (-2.31%)
Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out

Incyte (NASDAQ:INCY) Chief Medical Officer Steven Stein outlined the company’s development priorities across hematology, oncology and immunology, with a particular focus on its mutant CALR antibody 989,...

INCY : 100.01 (-2.31%)
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

The expanded agreement is one of the first major Pharma-AI collaborations to power large-scale foundation model training with a partner's proprietary experimental data ...

INCY : 100.01 (-2.31%)
Incyte Stock: Analyst Estimates & Ratings

As Incyte has considerably outperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

$SPX : 7,435.21 (+0.70%)
IBB : 167.27 (-0.69%)
INCY : 100.01 (-2.31%)
Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development

Incyte (Nasdaq:INCY) and Edison Scientific today announced a strategic collaboration to employ Kosmos, Edison’s AI scientist, for Incyte’s discovery and development work. This press...

INCY : 100.01 (-2.31%)
Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build

Incyte (NASDAQ:INCY) President and CEO Bill Meury said the company’s post-Jakafi growth profile has become “much clearer” over the past year, pointing to continued growth in its commercial business,...

INCY : 100.01 (-2.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 111.12
2nd Resistance Point 108.75
1st Resistance Point 105.56
Last Price 100.01
1st Support Level 100.00
2nd Support Level 97.63
3rd Support Level 94.44

See More

52-Week High 112.29
Last Price 100.01
Fibonacci 61.8% 94.89
Fibonacci 50% 89.52
Fibonacci 38.2% 84.14
52-Week Low 66.74

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.